홈 › 미만성 거대 B세포 림프종 › 오리건
오리건의 미만성 거대 B세포 림프종 임상 시험
미만성 거대 B세포 림프종 관련 연구 15개가 오리건 내 여러 지역에서 참여자를 모집하고 있습니다.
오리건의 도시
공식 연구 텍스트(영어)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001), Eugene
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Oncology Associates of Oregon, P.C, Eugene
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06806033Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- 외 2개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06649812A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Oregon Health & Science University (OHSU), Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
피험자 모집 중1/2상
6 Months – 25 Years · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06500273Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05890352Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
피험자 모집 중1/2상
13세 ~ 90세 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06533579Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- 외 2개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 15. 업데이트됨 · NCT05633615Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06784167Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Oregon Health and Science University Knight Cancer Institute, Portland
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Oregon Health and Science University Knight Cancer Institute, Portland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT04792489Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
- OHSU Knight Cancer Institute, Portland
피험자 모집 중1/2상
18세 ~ 75세 · 모든 성별 · 2026. 7. 7. 업데이트됨 · NCT06249191A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 10. 2. 업데이트됨 · NCT05780034ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.